A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study)

Psychotherapy and Psychosomatics

Volumn 81, Issue 2, 2012, Pages 87-97

  Fava, Maurizio ^a   Mischoulon, David ^a   Iosifescu, Dan ^d   Witte, Janet ^a   Pencina, Michael ^b   Flynn, Martina ^a   Harper, Linda ^c   Levy, Michael ^e   Rickels, Karl ^f   Pollack, Mark ^g  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON UNIVERSITY   (United States)

^c CNS Healthcare   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e Behavioral Medical Research   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g RUSH MEDICAL COLLEGE   (United States)

Author keywords

Antidepressant; Augmentation therapy; Major depressive disorder; Placebo

Indexed keywords

ARIPIPRAZOLE;

CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MENTAL PATIENT; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTPATIENT CARE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CONSTIPATION; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PIPERAZINES; PLACEBOS; QUINOLONES; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES; WEIGHT GAIN; YOUNG ADULT;

EID: 84856169699     PISSN: 00333190     EISSN: 14230348     Source Type: Journal    
DOI: 10.1159/000332050     Document Type: Review

References (25)

1. Fava M: Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003; 53: 649-659. (Pubitemid 39658481)
2. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M, STAR * D Study Team: Evaluation of outcomes with citalopram for depression using measurement-based care in STAR * D: implications for clinical practice. Am J Psychiatry 2006; 163: 28-40. (Pubitemid 43050100)
3. Nelson JC, Papakostas GI: Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009; 166: 980-991.
4. Berman RM, Marcus RN, Swanink R, Mc-Quade RD, Carson WH, Corey-Lisle PK, Khan A: The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68: 843-853. (Pubitemid 47015482)
5. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH, Thase ME, Berman RM: The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008; 28: 156-165. (Pubitemid 351417120)
6. Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, Carson WH, Adson D, Taylor L, Hazel J, Marcus RN: Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009; 14: 197-206.
7. Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389. (Pubitemid 9136500)
8. Fava M, Evins AE, Dorer DJ, Schoenfeld DA: The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom 2003; 72: 115-127. (Pubitemid 36469860)
9. Fava M, Iosifescu DV, Pedrelli P, Baer L: Reliability and validity of the Massachusetts general hospital cognitive and physical functioning questionnaire. Psychother Psychosom 2009; 78: 91-97.
10. Guy W: ECDEU Assessment Manual for Psychopharmacology. Rockville, US National Institutes of Health, 1976.
11. Kellner R: A symptom questionnaire. J Clin Psychiatry 1987; 48: 268-274. (Pubitemid 17108403)
12. Kroenke K, Spitzer RL, Williams JB: The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16: 606-613. (Pubitemid 32823891)
13. Targum SD, Pollack MH, Fava M: Redefining affective disorders: relevance for drug development. CNS Neurosci Ther 2008; 14: 2-9.
14. Trivedi MH, Rush AJ, Ibrahim HM, Carmody TJ, Biggs MM, Suppes T, Crismon ML, Shores-Wilson K, Toprac MG, Dennehy EB, Witte B, Kashner TM: The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med 2004; 34: 73-82. (Pubitemid 38139442)
15. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB: The 16-item Quick Inventory of Depressive Symptomatology (QIDS), Clinician Rating (QIDS-C), and Self-Report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003; 54: 573-583. (Pubitemid 37289444)
16. Chandler GM, Iosifescu DV, Pollack MH, Targum SD, Fava M: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). CNS Neurosci Ther 2010; 16: 322-325.
17. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
18. Fava M, Rankin MA, Alpert JE, Nierenberg AA, Worthington JJ: An open trial of oral sildenafilin antidepressant-induced sexual dysfunction. Psychother Psychosom 1998; 67: 328-331. (Pubitemid 28526065)
19. Tamura RN, Huang X: An examination of the efficiency of the sequential parallel design in psychiatric clinical trials. Clin Trials 2007; 4: 309-317. (Pubitemid 47572263)
20. Bech P: Fifty years with the Hamilton scales for anxiety and depression. Psychother Psychosom 2009; 78: 202-211.
21. Fava GA, Offidani E: The mechanisms of tolerance in antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1593-1602.
22. Chouinard G, Chouinard VA: Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother Psychosom 2008; 77: 69-77. (Pubitemid 351172096)
23. Sheffrin M, Driscoll HC, Lenze EJ, Mulsant BH, Pollock BC, Miller MD, Butters MA, Dew MA, Reynolds CF: Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission. J Clin Psychiatry 2009; 70: 208-213.
24. Bech P: Struggle for subtypes in primary and secondary depression and their mode-specific treatment or healing. Psychother Psychosom 2010; 79: 331-338.
25. Lichtenberg P, Belmaker RH: Subtyping major depressive disorder. Psychother Psychosom 2010; 79: 131-135.